|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 89.50 HKD | +0.56% |
|
+0.22% | +17.38% |
| Jan. 12 | Innovent Biologics: a Rising Star in Biopharma |  |
| Dec. 31 | Wall Street Cues, Economic Outlooks Roil Asian Stock Markets | MT |
| Capitalization | 139B 155B 19.91B 17.19B 15.97B 14.91B 27.69B 1,805B 29.85B 184B 72.51B 862B 74.63B 73.1B 3,142B | P/E ratio 2025 * |
81.9x | P/E ratio 2026 * | 43x |
|---|---|---|---|---|---|
| Enterprise value | 129B 144B 18.5B 15.98B 14.84B 13.85B 25.73B 1,677B 27.73B 171B 67.38B 801B 69.34B 67.92B 2,919B | EV / Sales 2025 * |
9.81x | EV / Sales 2026 * | 7.3x |
| Free-Float |
93.21% | Yield 2025 * |
-
| Yield 2026 * | 0.02% |
Last Transcript: Innovent Biologics, Inc.
| 1 day | +0.56% | ||
| 1 week | +0.22% | ||
| Current month | +17.38% | ||
| 1 month | +10.84% | ||
| 3 months | +3.05% | ||
| 6 months | +0.45% | ||
| Current year | +17.38% |
| 1 week | 88 |  | 92.75 |
| 1 month | 76 | | 92.75 |
| Current year | 76.75 | | 92.75 |
| 1 year | 30.75 | | 109.1 |
| 3 years | 27.3 | | 109.1 |
| 5 years | 18.06 | | 109.1 |
| 10 years | 14 | | 109.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
De Chao Yu
CEO | Chief Executive Officer | 62 | 2011-04-27 |
Fei You
DFI | Director of Finance/CFO | 47 | 2024-02-04 |
Ghang Shou Gao
CTO | Chief Tech/Sci/R&D Officer | - | 2020-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
De Chao Yu
CHM | Chairman | 62 | 2011-04-27 |
Charles Cooney
BRD | Director/Board Member | 81 | 2015-10-17 |
Hao Xi Ede
BRD | Director/Board Member | 67 | 2018-06-03 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -19.71% | 1.78% | 0 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.56% | +0.22% | +184.58% | +120.99% | 19.91B | |
| -1.20% | -7.97% | +7.55% | +0.68% | 75.21B | |
| -0.92% | +94.70% | +94.70% | +94.70% | 61.16B | |
| +2.35% | +4.24% | +45.53% | +229.86% | 58.53B | |
| +0.14% | +0.71% | -36.18% | -39.59% | 56.54B | |
| -2.46% | -12.37% | +16.98% | -43.22% | 24.12B | |
| +0.92% | -0.62% | +47.66% | +30.70% | 20.85B | |
| +10.10% | +1.37% | +68.46% | +1,369.50% | 18.8B | |
| +6.28% | +21.95% | +22.81% | -78.06% | 16.34B | |
| 0.00% | -1.28% | +125.69% | +778.57% | 14.7B | |
| Average | +1.58% | +1.86% | +57.78% | +246.41% | 36.62B | |
| Weighted average by Cap. | +0.72% | +0.49% | +42.50% | +150.14% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 13.14B 14.71B 1.89B 1.63B 1.51B 1.41B 2.62B 171B 2.83B 17.45B 6.87B 81.65B 7.07B 6.93B 298B | 17.29B 19.35B 2.48B 2.14B 1.99B 1.86B 3.45B 225B 3.72B 22.96B 9.04B 107B 9.31B 9.11B 392B |
| Net income | 1.66B 1.86B 239M 206M 192M 179M 332M 21.64B 358M 2.21B 869M 10.33B 895M 876M 37.67B | 3.19B 3.57B 458M 395M 367M 343M 637M 41.49B 686M 4.23B 1.67B 19.81B 1.72B 1.68B 72.22B |
| Net Debt | -9.82B -10.99B -1.41B -1.22B -1.13B -1.06B -1.96B -128B -2.11B -13.04B -5.13B -60.99B -5.28B -5.17B -222B | -12.37B -13.85B -1.78B -1.53B -1.42B -1.33B -2.47B -161B -2.66B -16.42B -6.47B -76.86B -6.66B -6.52B -280B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-16 | 89.50 $ | +0.56% | 6,745,760 |
| 26-01-15 | 89.00 $ | -0.50% | 11,496,890 |
| 26-01-14 | 89.45 $ | +0.11% | 9,961,587 |
| 26-01-13 | 89.35 $ | -0.11% | 15,968,500 |
| 26-01-12 | 89.45 $ | +0.17% | 13,377,300 |
Delayed Quote Hong Kong S.E., January 16, 2026 at 03:08 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1801 Stock
Select your edition
All financial news and data tailored to specific country editions
